Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.

Autor: Shimoni A; Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel Aviv, Israel. ashimoni@sheba.health.gov.il., Peczynski C; Sorbonne University, INSERM UMRs 938, Paris, France., Labopin M; Sorbonne University, INSERM UMRs 938, Paris, France., Kulagin A; Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia., Meijer E; VU University Medical Center, Department of Hematology, Amsterdam, The Netherlands., Cornelissen J; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands., Choi G; University Medical Center Groningen (UMCG), Dept. of Hematology, Groningen, The Netherlands., Sanz J; University Hospital La Fe, Hematology Department, Valencia, Spain., Rovira M; Hospital Clinic, Institute of Hematology & Oncology, Dept. of Hematology, Barcelona, Spain., Van Gorkom G; University Hospital Maastricht, Dept. Internal Med.Hematology /Oncology, Maastricht, The Netherlands., Kröger N; University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany., Koc Y; Medicana International Hospital Istanbul, Bone Marrow Transplant Unit, Istanbul, Turkey., Vydra J; Institute of Hematology and Blood Transfusion, Servicio de Hematología, Prague, Czech Republic., Diez-Martin JL; Hospital Gregorio Marañón, Sección de Trasplante de Medula Osea, Madrid, Spain., Solano C; Hospital Clínico de Valencia, Servicio de Hematología, Valencia, Spain., Patel A; Clatterbridge Cancer Centre - Liverpool, Royal Liverpool University Hospital, Clatterbridge Cancer Centre NHS Foundation Trust, Division of Stem Cell Transplantation and Haemato., Liverpool, United Kingdom., Chiusolo P; Universita Cattolica S. Cuore, Istituto di Ematologia, Ematologia, Rome, Italy., Ciceri F; Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy., Nagler A; Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel Aviv, Israel., Mohty M; Sorbonne University, INSERM UMRs 938, Paris, France.; Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.

Publikováno v: Leukemia [Leukemia] 2024 Oct 31. Date of Electronic Publication: 2024 Oct 31.

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

Autor: Angelillo P; San Raffaele Scientific Institute, Milan, Italy., Alarcon Tomas A; Clinica Puerta de Hierro, Madrid, Spain., Campodonico E; San Raffaele Scientific Institute, Milan, Italy., Novak U; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Gabellier L; University Hospital of Montpellier, Montpellier, France., Blau IW; Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Kwon M; Department of Hematology, Hospital General Unversitario, Madrid, Spain.; Universidad Complutense de Madrid, Madrid, Spain., Ram R; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Forcade E; CHU Bordeaux, Hopital Haut-Leveque, Pessac, France., Besley C; University Hospitals Bristol and Weston NHSFT, Bristol, United Kingdom., Vucinic V; Medical Clinic and Policinic 1, Leipzig, Germany., Kröger N; University Hospital Eppendorf, Hamburg, Germany., Corral LL; Hospital Universitario de Salamanca (Spain), IBSAL, CIBERONC, Salamanca, Spain., Vydra J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Ferrari S; ASST Papa Giovanni XXIII, Bergamo, Italy., von Tresckow B; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Rubio MT; CHRU NANCY, Nancy, France., Hernani R; Hospital Clínico de Valencia, Valencia, Spain., Sica S; Universita Cattolica S. Cuore, Rome, Italy., Stölzel F; University Hospital Schleswig-Holstein, Division of Stem Cell Transplantation and Cellular Immunotherapies, Kiel, Germany., Rovira M; Hospital Clinic, Barcelona, Spain., Wagner-Drouet E; University Medical Center Mainz, Mainz, Germany., Pérez-Simón JA; Department of Hematology, University Hospital Virgen Del Rocio, Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Sevilla, Spain., Castilla-Llorente C; Gustave Roussy Cancer Campus, Villejuif, France., Ferreri AJM; San Raffaele Scientific Institute, Milan, Italy., Hoogenboom JD; EBMT Leiden Study Unit, Leiden, The Netherlands., Sanchez Ortega I; EBMT Executive Office, Barcelona, Spain., Malard F; Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France., Kuball J; University Medical Center Utrecht, Utrecht, The Netherlands., Ruggeri A; San Raffaele Scientific Institute, Milan, Italy. annalisaruggeri80@hotmail.com.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.

Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms.

Autor: Chalandon Y; Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland., Eikema DJ; EBMT Leiden Statistical Unit, Leiden, The Netherlands., Moiseev I; RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia., Ciceri F; Ospedale San Raffaele s.r.l., Milan, Italy., Koster L; EBMT Leiden Study Unit, Leiden, The Netherlands., Vydra J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Passweg J; University Hospital Basel, Basel, Switzerland., Rovira M; Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain., Ozcelik T; Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Istanbul, Turkey., Gedde-Dahl T; Oslo University Hospital, Rikshospitalet Oslo, Oslo, Norway., Kröger N; University Hospital Eppendorf, Hamburg, Germany., Potter V; King's College Hospital, London, United Kingdom., Yakoub-Agha I; CHU de Lille, Univ Lille, INSERM U1286, INFINITE 59000, Lille, France., Rambaldi A; Department of Oncology and Hematology, University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Itälä-Remes M; Turku University Hospital, Turku, Finland., Tanase A; Fundeni Clinical Institute, Bucharest, Romania., Onida F; Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy., Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Scheid C; University of Cologne, Cologne, Germany., Drozd-Sokolowska J; University Clinical Centre, Medical University of Warsaw, Warsaw, Poland., Raj K; University College London Hospitals NHS Foundation Trust, London, United Kingdom., McLornan DP; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Robin M; Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4792-4802.

Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.

Autor: Sýkorová A; 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Folber F; Department of Internal Medicine, Haematology and Oncology, Masaryk University Hospital, Brno, Czech Republic., Polgárová K; 1st Department of Medicine-Department of Haematology, Charles University, General University Hospital, Prague, Czech Republic., Móciková H; Department of Haematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic., Ďuraš J; Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Steinerová K; Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic., Obr A; Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic., Heindorfer A; Department of Haematology, Hospital Liberec, Liberec, Czech Republic., Ladická M; Clinic of Oncohaematology, Medical Faculty of Comenius University and National Cancer Institute, Bratislava, Slovakia., Lukáčová Ľ; Oncology Clinic, J.A. Reiman Faculty Hospital, Prešov, Slovakia., Čellárová E; Department of Haematology, F.D. Roosevelt University Hospital, Banská Bystrica, Slovakia., Plameňová I; Clinic of Haematology and Transfusion Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia., Belada D; 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Janíková A; Department of Internal Medicine, Haematology and Oncology, Masaryk University Hospital, Brno, Czech Republic., Trněný M; 1st Department of Medicine-Department of Haematology, Charles University, General University Hospital, Prague, Czech Republic., Jančárková T; Department of Haematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic., Procházka V; Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic., Vranovský A; Clinic of Oncohaematology, Medical Faculty of Comenius University and National Cancer Institute, Bratislava, Slovakia., Králiková M; Department of Haematology, F.D. Roosevelt University Hospital, Banská Bystrica, Slovakia., Vydra J; Institute of Haematology and Blood Transfusion, Prague, Czech Republic., Smolej L; 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Drgoňa Ľ; Clinic of Oncohaematology, Medical Faculty of Comenius University and National Cancer Institute, Bratislava, Slovakia., Sedmina M; Department of Haematology, F.D. Roosevelt University Hospital, Banská Bystrica, Slovakia., Čermáková E; Department of Medical Biophysics, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Pytlík R; Institute of Haematology and Blood Transfusion, Prague, Czech Republic.

Publikováno v: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (17), pp. e70138.

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Autor: Nagler A; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel., Ngoya M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France., Galimard JE; EBMT Statistical Unit, Paris, France., Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France., Blau IW; Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Kröger N; University Hospital Eppendorf, Hamburg, Germany., Gedde-Dahl T; Oslo University Hospital, Rikshospitalet, Oslo, Norway., Schroeder T; University Hospital | Essen, Essen, Germany., Burns D; University Hospital Birmingham NHSTrust, Birmingham, UK., Salmenniemi U; HUCH Comprehensive Cancer Center, Helsinki, Finland., Rambaldi A; Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII Piazza OMS, Bergamo, Italy., Choi G; University Medical Center Groningen (UMCG), Groningen, The Netherlands., Peffault de Latour R; Saint-Louis Hospital, BMT Unit, Paris, France., Vydra J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Sengeloev H; Rigshospitalet, Herlev, Denmark., Eder M; Hannover Medical School, Hannover, Germany., Mielke S; Karolinska University Hospital, Stockholm, Sweden., Forcade E; CHU Bordeaux, Hopital Haut-Leveque, Pessac, France., Kulagin A; RM Gorbacheva Research Institute, Pavlov University, Petersburg, Russia., Ciceri F; IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Mohty M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Sep; Vol. 99 (9), pp. 1732-1745. Date of Electronic Publication: 2024 Jun 10.